BMRA heads into the final days of April with a notable split: short sellers have been retreating steadily as the company just unlocked a meaningful new commercial door.
The dominant story this week is the Medicare development. On April 16, Biomerica announced that a Medicare Administrative Contractor confirmed individual claim review eligibility for its inFoods® IBS diagnostic test. That opens a scalable reimbursement pathway — a structural positive for a micro-cap company that posted Q3 sales of just $987,000 against a net loss of $1.31 million. Days later, the company also announced Canadian market entry for inFoods IBS through partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs. Now, with data from the inFoods program accepted for presentation at Digestive Disease Week 2026 (Chicago, May 2–5), the clinical and commercial narrative is building momentum even as revenues remain thin.
Short positioning has moved sharply in the company's favour over the past month. Estimated short interest peaked above 108,000 shares on April 2–3, representing roughly 3.7% of the free float. By April 28 that number had fallen to around 69,400 shares — a drop of roughly 40% in four weeks, bringing SI % of free float down to approximately 2.4%. The week-on-week decline is more modest at around 5%, suggesting the most aggressive covering happened in early-to-mid April around the Medicare announcement and earnings release. Borrowing costs have also eased materially: the cost to borrow peaked above 2.6% in early April and has since compressed to 1.29%, roughly half that level. Availability in the lending market remains well-supplied relative to the short position, with no signs of stress. The overall picture is one of short sellers quietly walking away rather than being squeezed out.
The ORTEX short score is running near the neutral midpoint at 49.9, having briefly dipped into the high-40s in mid-April before recovering. That reading corroborates the directional story: shorts aren't piling in, but they haven't completely abandoned their positions either. Days-to-cover of 5.1 gives the short base a modest buffer. The RSI14 at 53 reflects an unremarkable technical setup — the stock has gained just under 1% this week and about 8.5% over the past month to trade at $2.18, still down 13.5% year to date.
The most recent earnings print (Q3, for the period ended February 28) revealed revenue of $987,000 — down from $1.12 million a year earlier — while the nine-month net loss narrowed to $2.63 million from $3.43 million. The loss-per-share improvement reflects both some cost discipline and a share count shift. The company's market cap remains firmly in micro-cap territory at roughly $6.7 million. Ownership is concentrated: CEO Zackary Irani holds approximately 4.4% of shares, with a cluster of other named individuals each holding between 1% and 1.5%. Institutional holders — including Vanguard with 21,000 shares and BlackRock with 18,600 — hold tiny stakes by their own standards. DRW Holdings added a small position in late 2025. The holder count of just 17 institutions reflects how thinly followed this name remains.
Closest peers had a rougher week. VBIO fell nearly 28% on the day and 13% on the week. TRIB dropped close to 5% on the day. CLPT eked out a modest 3.4% weekly gain. Against that backdrop, BMRA's near-flat week looks comparatively stable, though the correlation readings are low enough that direct peer reads should be treated cautiously.
The next focal point for the stock is the Digestive Disease Week conference in Chicago from May 2 to 5, where inFoods IBS data will be presented — the first significant clinical platform the company has had since the Medicare announcement, and the clearest near-term moment to watch for any shift in the story.
See the live data behind this article on ORTEX.
Open BMRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
